Health Canada Releases Draft Revised Quality Guide for Natural Health Products: What Manufacturers Need to Know

Health Canada has released a draft revised Quality Guide for Natural Health Products (NHPs) for public consultation, representing the first comprehensive update to the guidance since 2015.

The consultation is open from 20 July 2026 to 20 September 2026, giving manufacturers, Product Licence holders, ingredient suppliers, contract manufacturers, testing laboratories, and regulatory professionals an opportunity to review the proposed revisions and provide feedback before the guidance is finalized.

Although the Quality Guide is not a regulation, it plays a critical role in explaining Health Canada’s expectations for demonstrating the quality, safety, identity, potency, and consistency of Natural Health Products marketed in Canada. Companies involved in the Canadian NHP industry should carefully review the proposed revisions and assess how they may affect existing quality systems.

Why Is Health Canada Updating the Quality Guide?

Over the past decade, Canada’s Natural Health Products industry has evolved significantly.

Manufacturers now use more sophisticated analytical technologies, increasingly complex formulations, globally sourced ingredients, and advanced manufacturing processes. At the same time, Health Canada has been modernizing its regulatory framework to improve efficiency while maintaining high standards for product quality and consumer safety.

The revised guide aims to provide clearer expectations, improve consistency across the industry, and support a more modern, risk-based approach to quality management.

What Is the Natural Health Products Quality Guide?

The Quality Guide is an interpretive guidance document that explains how Health Canada expects applicants and licence holders to demonstrate compliance with the quality requirements established under the Natural Health Products Regulations.

The guide addresses several critical quality topics, including:

Identity testing
Purity requirements
Potency verification
Manufacturing controls
Finished Product Specifications (FPS)
Stability programs
Analytical methods
Documentation requirements
Quality assurance systems

Although guidance documents do not create new legal obligations, they are frequently referenced during Product Licence reviews, GMP inspections, and compliance activities.

Why This Public Consultation Matters

Health Canada is inviting stakeholders to provide feedback before the final guide is published.

This consultation allows industry participants to:

Identify areas requiring clarification
Highlight implementation challenges
Recommend scientifically justified alternatives
Improve consistency across the Natural Health Products sector
Support practical implementation of quality expectations

Early participation gives organizations an opportunity to influence the final guidance before it becomes Health Canada’s official interpretation.

Potential Impact on Natural Health Product Manufacturers

Once finalized, the revised guide may influence how manufacturers develop and maintain quality documentation.

Companies should evaluate whether updates may be required for:

Finished Product Specifications (FPS)
Raw material specifications
Analytical testing methods
Stability studies
Supplier qualification programs
Manufacturing documentation
Quality Management Systems (QMS)
Standard Operating Procedures (SOPs)

Organizations with mature quality systems are likely to adapt more efficiently to the revised expectations.

Why Gap Assessments Should Begin Now

Waiting until the final guidance is published may delay implementation and increase compliance risks. Instead, companies should begin conducting internal gap assessments by reviewing:

Current Finished Product Specifications
Raw material specifications
Analytical methods
Stability protocols
Supplier qualification procedures
Quality agreements
SOPs
Quality Management System documentation

Early preparation allows organizations to identify potential improvements while sufficient time remains for implementation.

What Existing Product Licence Holders Should Know

Existing Product Licence holders should recognize that guidance documents explain Health Canada’s interpretation of existing regulatory requirements rather than introducing entirely new legislation.
Nevertheless, organizations should evaluate whether revisions to their quality systems, documentation, or internal procedures are appropriate once the final guide is released.

Maintaining inspection-ready documentation and robust quality systems remains essential.

Consultation Timeline

Consultation Opens
20 July 2026

Consultation Closes
20 September 2026

Companies wishing to provide feedback should review the draft guidance and submit comments within the consultation period.
Health Canada’s recent regulatory modernization efforts also include changes to Finished Product Specifications (FPS) for Class II and III Product Licence Applications. Learn more in our guide on Health Canada Removes FPS Submission Requirement for NHP Applications.

How Fiducia Globus Can Help

Fiducia Globus supports Natural Health Product manufacturers, importers, and Product Licence holders through:

Product Licence Application support
Quality gap assessments
Finished Product Specification (FPS) development and review
GMP compliance consulting
SOP development and review
Quality Management System improvements
Regulatory documentation reviews
Canadian market entry consulting
Ongoing Health Canada compliance support

Our regulatory specialists help organizations strengthen quality systems while preparing for evolving Health Canada expectations.

Frequently Asked Questions

Is the revised Quality Guide legally binding?
No. The Quality Guide is an interpretive guidance document that explains Health Canada’s expectations for complying with the Natural Health Products Regulations.

Who should review the draft guide?
Manufacturers, Product Licence holders, ingredient suppliers, testing laboratories, contract manufacturers, consultants, and regulatory professionals involved with Natural Health Products.

Will existing Product Licence holders need to make changes?
Possibly. Organizations should evaluate their current quality systems and determine whether updates may be appropriate once the final guidance is published.

Should companies wait until the consultation ends?
No. Conducting a preliminary gap assessment now can help organizations prepare for future implementation and reduce compliance risks.

Conclusion

Health Canada’s draft revised Quality Guide represents another important milestone in the modernization of Canada’s Natural Health Products regulatory framework.

Although the consultation does not immediately change regulatory requirements, it provides valuable insight into Health Canada’s evolving expectations for quality management and compliance.

Organizations that review the draft guidance, conduct proactive gap assessments, and participate in the consultation process will be better positioned to adapt once the final guide is published.